Fresh analysis indicates that people who discontinue popular slimming jabs like semaglutide or tirzepatide can put back on reduced body mass at a significantly accelerated pace than those who end traditional lifestyle regimens.
Research printed in a prominent health publication shows that while obese people can lose a large proportion of their total mass while using the jabs, the weight comes back at an estimated rate of nearly a kilo each month once they quit.
"Users buying these treatments need to be informed of the potential of fast rebound weight gain when the treatment is stopped," cautioned expert Dr. Susan Jebb.
This pace of recovery means a reversion to starting mass within about one and a half years.
Analyzing Therapies
The analysis, which looked at dozens of trials involving over 9,000 of patients, compared the results of the injectable medications with older methods.
Scientists emphasize that people who shed pounds through lifestyle changes alone usually see a slower weight regain—around 0.1 kg a month—post-intervention.
The Reason for the Rapid Rebound
Doctors believe the mode of action of the jabs is key to understanding the amplified weight return.
The injections copy a natural hormone called glucagon-like peptide-1, which helps regulate feelings of fullness.
"Long-term administration of GLP-1 concentrations far above than the body's typical production could lead to the body to produce less of its own natural hormone, and could lessen responsiveness to its effects," said Dr. Adam Collins, a nutrition expert.
"Withdrawal of this hormone supplement leads to appetite is no longer kept in check, making binge eating far more likely."
A Chronic Disease?
Health authorities suggest the jabs for people with weight-linked medical conditions, accompanied by recommended lifestyle changes.
Many experts argue that, given the high risk of weight regain, the treatment is often life-long.
This perspective is reinforced by pharmaceutical companies, who say that the findings "highlight the chronic nature of excess weight," comparing it to managing conditions like high blood pressure.
Patient Experiences
Users who have discontinued the medication explain a intense return of cravings.
"I experienced something flipping and you become starving," recalled a patient.
This difficulty is compounded if patients have not adopted permanent dietary or behavioural modifications during therapy.
Widespread Adoption
Survey data show that a significant number of people in the UK have used these injections in the last 12 months, with interest continuing to grow.
- Use is greater among females than males.
- The 40s and 50s demographic shows the highest level of interest.
- A large proportion obtain the medications through private healthcare rather than the NHS.
Finally, experts stress that while these medications are powerful tools for weight loss, they are not a standalone solution and maintained weight loss likely depends on integrated behavioural support.
